|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 2002; 39:90-95 © 2002 by the American College of Cardiology Foundation |
* Department of Internal Medicine and Cardiovascular Sciences, University Federico II School of Medicine, Naples, Italy
Manuscript received June 12, 2001; revised manuscript received September 4, 2001, accepted September 7, 2001.
* Reprint requests and correspondence: Dr. Luigi Saccà, Medicina Interna, Via Pansini 5, 80131 Napoli, Italy.
sacca{at}unina.it
OBJECTIVES: The goal of this study was to test the hypothesis that growth hormone (GH) administration to patients with chronic heart failure (CHF) corrects their vascular dysfunction.
BACKGROUND: Endothelial dysfunction is a prominent feature of CHF. Recent evidence indicates that GH plays a role in vascular reactivity.
METHODS: We studied vascular reactivity in 16 patients with CHF (New York Heart Association class II to III) before and after three months of GH (4 IU subcutaneously every other day) or placebo administration in a randomized, double-blind trial. We measured forearm blood flow (FBF) by strain-gauge plethysmography during intrabrachial, graded infusion of acetylcholine (ACh) and sodium nitroprusside (NP). We also measured the forearm balance of nitrite and cyclic guanosine monophosphate (cGMP) before and during ACh infusion. Maximal oxygen uptake (VO2max) was measured by breath-to-breath respiratory gas analysis.
RESULTS: Before treatment, the response of FBF to ACh was flat (p = NS). Growth hormone, but not placebo, greatly improved this response (p = 0.03) and, concomitantly, increased the forearm release of nitrite and cGMP (p < 0.05). Growth hormone also potentiated the FBF response to NP (p = 0.013). Growth hormone interacted with ACh response (p = 0.01) but not with the response to NP (p = NS). Accordingly, GH enhanced the slope of the dose-response curve to ACh (p < 0.05) but not to NP. The VO2max increased significantly after GH treatment (20 ± 2 and 26 ± 2 ml ·Kg–1· min–1 before and after GH treatment, respectively, p < 0.05) but not after placebo.
CONCLUSIONS: A three-month treatment with GH corrected endothelial dysfunction and improved non-endothelium-dependent vasodilation in patients with CHF. The data highlight the potential role of GH in the progression of congestive heart failure.
| ||||||||||||||||||||||||||||
This article has been cited by other articles:
|
|
 |
|
  M. Salerno, U. Oliviero, T. Lettiero, V. Guardasole, D. M. Mattiacci, L. Saldamarco, D. Capalbo, A. Lucariello, L. Sacca, and A. Cittadini Long-Term Cardiovascular Effects of Levothyroxine Therapy in Young Adults with Congenital Hypothyroidism J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2486 - 2491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Li, J.-P. del Rincon, L. A. Jahn, Y. Wu, B. Gaylinn, M. O. Thorner, and Z. Liu Growth Hormone Exerts Acute Vascular Effects Independent of Systemic or Muscle Insulin-like Growth Factor I J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1379 - 1385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fazio, E. A. Palmieri, F. Affuso, A. Cittadini, G. Castellano, T. Russo, A. Ruvolo, R. Napoli, and L. Sacca Effects of Growth Hormone on Exercise Capacity and Cardiopulmonary Performance in Patients with Chronic Heart Failure J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4218 - 4223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wallander, A. Norhammar, K. Malmberg, J. Ohrvik, L. Ryden, and K. Brismar IGF Binding Protein 1 Predicts Cardiovascular Morbidity and Mortality in Patients With Acute Myocardial Infarction and Type 2 Diabetes Diabetes Care, September 1, 2007; 30(9): 2343 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Napoli, V. Guardasole, V. Angelini, E. Zarra, D. Terracciano, C. D'Anna, M. Matarazzo, U. Oliviero, V. Macchia, and L. Sacca Acute Effects of Triiodothyronine on Endothelial Function in Human Subjects J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 250 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Le Corvoisier, L. Hittinger, P. Chanson, O. Montagne, I. Macquin-Mavier, and P. Maison Cardiac Effects of Growth Hormone Treatment in Chronic Heart Failure: A Meta-Analysis J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 180 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. D. Monti, E. Setola, G. Fragasso, R. P. Camisasca, P. Lucotti, E. Galluccio, A. Origgi, A. Margonato, and P. Piatti Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E54 - E59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Marleau, M. Mulumba, D. Lamontagne, and H. Ong Cardiac and peripheral actions of growth hormone and its releasing peptides: Relevance for the treatment of cardiomyopathies Cardiovasc Res, January 1, 2006; 69(1): 26 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Kleinz, J. J. Maguire, J. N. Skepper, and A. P. Davenport Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man Cardiovasc Res, January 1, 2006; 69(1): 227 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Lipshultz, S. A. Vlach, S. R. Lipsitz, S. E. Sallan, M. L. Schwartz, and S. D. Colan Cardiac Changes Associated With Growth Hormone Therapy Among Children Treated With Anthracyclines Pediatrics, June 1, 2005; 115(6): 1613 - 1622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C Wollert and H. Drexler Growth hormone and proinflammatory cytokine activation in heart failure: Just a new verse to an old sirens' song? Eur. Heart J., December 2, 2003; 24(24): 2164 - 2165. [Full Text] [PDF]
|
|
|
|
|
|
S. Adamopoulos, J. T. Parissis, I. Paraskevaidis, D. Karatzas, E. Livanis, M. Georgiadis, G. Karavolias, D. Mitropoulos, D. Degiannis, and D. Th. Kremastinos Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy Eur. Heart J., December 2, 2003; 24(24): 2186 - 2196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Napoli, V. Guardasole, V. Angelini, F. D'Amico, E. Zarra, M. Matarazzo, and L. Sacca Acute Effects of Growth Hormone on Vascular Function in Human Subjects J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2817 - 2820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Can Growth Hormone Restore Vascular Function in Heart Failure? Journal Watch Cardiology, March 15, 2002; 2002(315): 2 - 2. [Full Text]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
